Replies to post #8654 on Amarin Corp Plc (AMRN)

[Biobillionair]

JL,
Haven't read through all your posts...did you cover this? Because the combo of ASA and EPA is essentially a Resolvin drug, exerting inhibitory action on leukocyte transendothelial migration and IL-2 production. That's a BFD, right? Will

"Aspirin exerts its actions by the inhibition of both COX-1 and COX-2 (cyclooxygenase 1 and 2) which has a direct negative effect on prostaglandin synthesis. It irreversibly acetylates COX-2 which loses the ability to generate prostaglandin intermediates. However, COX-2 retains oxygenase activity which results in the production of several types of anti-inflammatory mediators. This pathway describes the aspirin triggered conversion of : 5Z8Z11Z14Z17Z-EICOSAPENTAENOATE to anti-inflammatory mediators of the resolvin E1 and 2.. About this Pathway Aspirin mediated acetylation of COX-2 triggers the synthesis of resolvins E1 and E2 from eicosapentaenoate. Resolvin E1 has been found to be 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoate . The enzyme 5-lipooxygenase is pivotal in the catalysis of 18-HEPE to 5S,18-HEPE which leads to the downstream production of resolvins E1 and E2 . Resolvin E1 has proven inhibitory action on leukocyte transendothelial migration and IL-2 production."

[Ajax133]

JL: Since prescribing Physicians are not reading your
stellar posts, it occurred to me that what we need is
for AMRN to get top Lipid Specialists and Cardiologists
to write articles about the potent anti inflammatory
effects in PEER reviewed journals. This will start the
long overdue dissemination of this game changing information.
Short of that we have a mountain to climb.